Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

Reports of the FTC’s plan come just a couple of days after the regulator published its long-awaited report on the PBM sector, which concluded that their market dominance has “dire consequences ...

Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy ...